Sumitomo Dainippon confirms takeover talks with Cynata

19 July 2019
cynata-big-1

Australian stem cell and regenerative medicine firm Cynata Therapeutics (ASX: CYP) saw its shares leap as much as 15.5% to A$1.85, after it revealed that it has received an indicative, non-binding and conditional proposal from Japan’s Sumitomo Dainippon Pharma (TYO: 4506) regarding a possible acquisition at a price of $2.00 cash per share – around $202 million in total - by way of a scheme of arrangement.

The release advises that the Cynata board has decided to grant non-exclusive due diligence access to Sumitomo Dainippon Pharma.

It also stated that Cynata has continued engagement with certain other parties in relation to making a proposal. Cynata’s discussions with such other parties have ceased.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology